Melissa Gelormini - Homology Medicines Senior Resources
| FIXXDelisted Stock | USD 1.09 0.06 5.83% |
Executive
Melissa Gelormini is Senior Resources of Homology Medicines
| Phone | 781 301 7277 |
| Web | https://www.homologymedicines.com |
Homology Medicines Management Efficiency
The company has return on total asset (ROA) of (0.364) % which means that it has lost $0.364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9002) %, meaning that it created substantial loss on money invested by shareholders. Homology Medicines' management efficiency ratios could be used to measure how well Homology Medicines manages its routine affairs as well as how well it operates its assets and liabilities.Homology Medicines currently holds 1.32 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Homology Medicines has a current ratio of 8.27, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Homology Medicines' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Uneek Mehra | 4D Molecular Therapeutics | 52 | |
| Noriyuki MD | 4D Molecular Therapeutics | 61 | |
| John Lunger | Adaptimmune Therapeutics Plc | 54 | |
| MD BA | Adaptimmune Therapeutics Plc | 60 | |
| Sue Browne | Passage Bio | N/A | |
| Karen Carothers | 4D Molecular Therapeutics | 73 | |
| Dana Lynch | Adaptimmune Therapeutics Plc | N/A | |
| Gregory Fuest | Passage Bio | N/A | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| Stuart Henderson | Passage Bio | N/A | |
| Eden Fucci | Passage Bio | N/A | |
| BA ACA | Adaptimmune Therapeutics Plc | 54 | |
| Cintia PharmD | Adaptimmune Therapeutics Plc | 50 | |
| Huw Nash | Stoke Therapeutics | 57 | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
| Kerry Sharp | Adaptimmune Therapeutics Plc | N/A | |
| Dr JD | 4D Molecular Therapeutics | 51 | |
| Thomas Leggett | Stoke Therapeutics | 47 | |
| Erika Jones | Black Diamond Therapeutics | 39 | |
| FAAAAI FAAP | 4D Molecular Therapeutics | 63 | |
| Karl Whitney | Passage Bio | N/A | |
Management Performance
| Return On Equity | -0.9 | |||
| Return On Asset | -0.36 |
Homology Medicines Leadership Team
Elected by the shareholders, the Homology Medicines' board of directors comprises two types of representatives: Homology Medicines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Homology. The board's role is to monitor Homology Medicines' management team and ensure that shareholders' interests are well served. Homology Medicines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Homology Medicines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael MBA, Chief Officer | ||
| Melissa Gelormini, Senior Resources | ||
| Saswati Chatterjee, CoFounder Board | ||
| CPA Michaud, Corporate Finance | ||
| Paul JD, President COO | ||
| Deborah Kinch, Chief Officer | ||
| Julie MD, Sr Operations | ||
| Theresa McNeely, Chief Advocate | ||
| Cara Mayfield, Director Communications | ||
| Albert Seymour, Chief Scientific Officer |
Homology Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Homology Medicines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.9 | |||
| Return On Asset | -0.36 | |||
| Operating Margin | (78.85) % | |||
| Current Valuation | (27 M) | |||
| Shares Outstanding | 3.23 M | |||
| Shares Owned By Insiders | 9.20 % | |||
| Shares Owned By Institutions | 46.75 % | |||
| Number Of Shares Shorted | 338.72 K | |||
| Price To Earning | (10.00) X | |||
| Price To Book | 0.04 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Homology Stock
If you are still planning to invest in Homology Medicines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Homology Medicines' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |